Securities Code: 300871 Securities Abbreviation: Huasheng Biology Announcement No.: 2026-050
Wuhan Huasheng Biological Technology Co., Ltd. Announcement on Progress of Providing Guarantees for Subsidiaries
The Company and the Board of Directors guarantee that the content of the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
I. Overview of Guarantee Situation
Wuhan Huasheng Biological Technology Co., Ltd. (hereinafter referred to as the "Company") held its Fourth Board of Directors Meeting on February 4, 2026, and its 2026 First Extraordinary Shareholders' Meeting on February 25, 2026. Both meetings deliberated and approved the "Proposal on the Company and its Subsidiaries Applying for Comprehensive Credit Lines from Financial Institutions in 2026 and Related Guarantees and Connected Transactions." It was agreed that the Company and its subsidiaries would apply for a comprehensive credit line not exceeding RMB 1,200 million (inclusive) from financial institutions in 2026. It was also agreed that the Company would provide a guarantee limit not exceeding RMB 500 million for subsidiaries within the scope of the consolidated financial statements. Concurrently, Mr. Zhang Weiyuan, the actual controller of the Company, and Ms. Yu Jia'e provided gratuitous guarantees for the Company and its subsidiaries' application for comprehensive credit lines from financial institutions. The validity period of the aforementioned credit line and guarantee limit is 12 months from the date of approval by the 2026 First Extraordinary Shareholders' Meeting. For detailed content, please refer to the "Announcement on the Company and its Subsidiaries Applying for Comprehensive Credit Lines from Financial Institutions in 2026 and Related Guarantees and Connected Transactions" disclosed by the Company on the Juchao Information Network (www.cninfo.com.cn) on February 6, 2026.